Absence of an interaction between iron and mycophenolate mofetil absorption

被引:8
|
作者
Ducray, Patricia Sanwald
Banken, Ludger
Gerber, Marianne
Boutouyrie, Bruno
Zandt, Hagen
机构
[1] F Hoffmann La Roche & Co Ltd, Dept Clin Pharmacol, CH-4070 Basel, Switzerland
[2] Inst Pharmacol Clin Roche, Strasbourg, France
关键词
absorption; iron ion; mycophenolate mofetil; pharmacokinetics;
D O I
10.1111/j.1365-2125.2005.02541.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim To determine whether concomitant iron affects the absorption of mycophenolate mofetil. Methods An open-label, single centre, randomized, crossover trial was conducted in 16 healthy males. Fasting subjects received mycophenolate mofetil alone (treatment A) or co-administered with iron (treatment B). Results The mycophenolic acid AUC(0,24 h) for treatments A and B were 42.5 +/- 10.5 and 44.7 +/- 12.4 mu g ml(-1) h, respectively. ANOVA modelling showed the relative bioavailability of mycophenolate mofetil to be similar for the two treatments (90% confidence interval 0.92, 1.19). Conclusions There was no interaction between mycophenolate mofetil and iron supplements administered concomitantly to healthy fasting subjects.
引用
收藏
页码:492 / 495
页数:4
相关论文
共 50 条
  • [21] MYCOPHENOLATE MOFETIL
    SOLLINGER, HW
    KIDNEY INTERNATIONAL, 1995, 48 : S14 - S17
  • [22] Oral and intestinal absorption of mycophenolate mofetil - An intubation study in dogs
    Ghahramani, P
    Rashford, M
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (10): : 1190 - 1190
  • [23] Drug interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphate-glucuronosyltransferase
    Kuypers, DRJ
    Verleden, G
    Naesens, M
    Vanrenterghem, Y
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (01) : 81 - 88
  • [24] Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil
    Lemaitre, Florian
    Ben Ali, Zeineb
    Tron, Camille
    Jezequel, Caroline
    Boglione-Kerrien, Christelle
    Verdier, Marie-Clemence
    Guyader, Dominique
    Bellissant, Eric
    THERAPEUTIC DRUG MONITORING, 2017, 39 (04) : 305 - 307
  • [25] No Evidence of a Drug-Drug Interaction Between Letermovir (MK-8228) and Mycophenolate Mofetil
    Marshall, William L.
    Badshah, Cyrus
    Liu, Fang
    Kraft, Walter
    Colon-Gonzalez, Francheska
    van Schanke, Arne
    de Haes, Joanna Udo
    Kantesaria, Bhavna
    Hulskotte, Ellen
    Cho, Carolyn
    Butterton, Joan R.
    Marcantonio, Eugene E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S243 - S243
  • [26] Managing drug-drug interaction between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir and Mycophenolate mofetil
    Tron, C.
    Lemaitre, F.
    Ben Ali, Z.
    Leven, C.
    Jezequel, C.
    Boglione-Kerrien, C.
    Verdier, M. C.
    Guyader, D.
    Bellissant, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 85 - 85
  • [27] Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: A case report
    Cattaneo, Dario
    Bitto, Alessandra
    Baldelli, Sara
    Cortinovis, Monica
    Gotti, Eliana
    Perico, Norberto
    Remuzzi, Giuseppe
    TRANSPLANTATION, 2008, 85 (06) : 921 - 922
  • [28] Probable Drug Interaction Between Intravenous Ciprofloxacin and Mycophenolate Mofetil in a Bone Marrow Transplant Recipient
    Goutelle, Sylvain
    Mialou, Valerie
    Gouraud, Aurore
    Parant, Francois
    Bleyzac, Nathalie
    PHARMACOTHERAPY, 2011, 31 (01): : 114 - 114
  • [29] Interaction of mycophenolate mofetil and HLA matching on renal allograft survival
    Meier-Kriesche, HU
    Ojo, AO
    Leichtman, AB
    Magee, JC
    Rudich, SM
    Hanson, JA
    Cibrik, DM
    Kaplan, B
    TRANSPLANTATION, 2001, 71 (03) : 398 - 401
  • [30] Omeprazole Impairs the Absorption of Mycophenolate Mofetil But Not of Enteric-Coated Mycophenolate Sodium in Healthy Volunteers
    Kees, M. G.
    Steinke, T.
    Moritz, S.
    Rupprecht, K.
    Paulus, E. M.
    Kees, F.
    Bucher, M.
    Faerber, L.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (08): : 1265 - 1272